Remdesivir (GS-5734; RDV) is a phosphoramidate prodrug of modified adenosine nucleotide analog with a broad-spectrum antiviral activity against multiple RNA viruses including filoviruses, paramyxoviruses, flaviviruses and coronaviruses. RDV is intracellularly metabolized to the active nucleoside triphosphate form that directly inhibits viral replication following its incorporation into viral RNA by viral RNA-dependent RNA polymerases. The molecular mechanism leading to the termination of viral RNA synthesis as well as key structural interactions with the target viral RNA polymerases have been established. Multiple independent studies have established the antiviral activity of RDV against SARS-CoV-2 both in vitro and in animal models. In several randomized controlled clinical trials, 5- to 10-day course of treatment with RDV administrated once-daily by intravenous infusion has demonstrated efficacy in hospitalized COVID-19 patients by significantly reducing disease progression and accelerating time to recovery. In October 2020, RDV has been approved by US FDA as the first treatment for COVID-19 in hospitalized patients. RDV is currently being tested in combinations with a variety of other agents including anti-inflammatory drugs as well as neutralizing antibodies to potentially further enhance the clinical impact in hospitalized settings. In addition, a newly developed inhaled formulation of RDV is undergoing a Phase2 evaluation in out-patient settings with a goal to prevent disease progression and reduce hospitalization following COVID-19 diagnosis.

Update on Remdesivir for the treatment of COVID-19

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.